Sebastien Anguille
Overview
Explore the profile of Sebastien Anguille including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boen H, Pype L, Papadimitriou K, Altintas S, Teuwen L, Anguille S, et al.
Cardiooncology
. 2025 Mar;
11(1):27.
PMID: 40087712
Background: SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with cancer therapy-related cardiac dysfunction (CTRCD) circulating SERPINA3 was elevated compared to age-matched...
2.
Debie Y, Garcia-Fogeda I, Willem L, Roelant E, Verbruggen L, Vanhoutte G, et al.
Sci Rep
. 2025 Mar;
15(1):7858.
PMID: 40050359
The level of protection against SARS-CoV-2 breakthrough infections conferred by the presence of anti-S1 SARS-CoV-2 antibodies (IgGs) in cancer patients is still understudied. This work examines the existence of an...
3.
Lonez C, Bolsee J, Huberty F, Nguyen T, Jacques-Hespel C, Anguille S, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004122
With the success of chimeric antigen receptor (CAR) T-cell therapy in B-cell malignancies, efforts are being made to extend this therapy to other malignancies and broader patient populations. However, limitations...
4.
Berneman Z, De Laere M, Germonpre P, Huizing M, Willemen Y, Lion E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):9.
PMID: 39849594
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant...
5.
Heyrman B, Meers S, Sid S, Put N, Theunissen K, Van Eygen K, et al.
EJHaem
. 2024 Oct;
5(5):1096-1099.
PMID: 39415916
No abstract available.
6.
Gielis S, Flumens D, van der Heijden S, Versteven M, De Reu H, Bartholomeus E, et al.
Ann Hematol
. 2024 Sep;
104(1):317-333.
PMID: 39259326
The Wilms' tumor protein 1 (WT1) is a well-known and prioritized tumor-associated antigen expressed in numerous solid and blood tumors. Its abundance and immunogenicity have led to the development of...
7.
Van den Bossche J, De Laere M, Deschepper K, Germonpre P, Valcke Y, Lamont J, et al.
PLoS One
. 2024 Jul;
19(7):e0307204.
PMID: 39008481
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing...
8.
Van Genechten T, De Laere M, Van den Bossche J, Stein B, De Rycke K, Deschepper C, et al.
BMJ Open
. 2024 Mar;
14(3):e077613.
PMID: 38503417
Introduction: Diffuse intrinsic pontine glioma (DIPG) and paediatric high-grade glioma (pHGG) are aggressive glial tumours, for which conventional treatment modalities fall short. Dendritic cell (DC)-based immunotherapy is being investigated as...
9.
Heyrman B, Meers S, Velde A, Anguille S
Clin Pract
. 2023 Dec;
13(6):1520-1531.
PMID: 38131682
Despite the motivation of oncology patients to take part in clinical trials, only a minority of them are enrolled in clinical trials. Implementation of new practical procedures can become a...
10.
Heyrman B, Meers S, De Becker A, Wouters K, Van Hoof A, Velde A, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444406
Patients with myelodysplastic syndromes suffer from an impaired quality of life that is only partially explained by physical symptoms. In an observational study, we aimed to investigate the impact of...